Literature DB >> 27722965

The social cost of drugs in France in 2010.

Pierre Kopp1, Marysia Ogrodnik2.   

Abstract

The social cost of drugs is the monetary cost of both the consequences of their trade and their consumption. In this paper, drugs considered are tobacco and alcohol, which are legal, plus those that are illegal. The social cost is the sum of the external cost: value of loss in quality of life, value of years of life lost and value of loss in productivity, plus public expenditure. Public expenditure consists of public spending on medical care, prevention, and law enforcement, minus savings from unpaid pensions and taxes levied on tobacco and alcohol. The parameters for the calculations have used the recommendations of a French governmental working group (2013) Quinet, L'évaluation socioéconomique des investissements publics [Internet], Centre d'Analyse Stratégique, 2013, http://www.strategie.gouv.fr/sites/strategie.gouv.fr/files/archives/CGSP_Evaluation_socioeconomique_17092013.pdf , and the health data were derived from the scientific literature. The social costs are €122 billion for tobacco, €118 billion for alcohol, and €8.7 billion for illegal drugs. The largest fraction of the costs (53, 56, and 31 %, respectively) derives from the number of deaths, 79,000 for tobacco, 49,000 for alcohol, and 1600 for illegal drugs, given the high cost of a year of life lost (€115,000). The external cost corresponds to 86, 97, and 68 % of the social cost, respectively, for tobacco, alcohol, and illegal drugs. The annual drug-related net expenditure represents €13.9, €3.0, and €2.3 billion, respectively, for tobacco, alcohol, and illegal drugs. The tax revenues on tobacco and alcohol, €10.4 and €3.2 billion, represent less than half of the corresponding healthcare costs, which are €25.9 and €7.7 billion.

Entities:  

Keywords:  Alcohol; Drugs; Social cost; Tobacco

Mesh:

Substances:

Year:  2016        PMID: 27722965     DOI: 10.1007/s10198-016-0835-9

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  6 in total

1.  Are calculations of the economic costs of drug abuse either possible or useful?

Authors:  P Reuter
Journal:  Addiction       Date:  1999-05       Impact factor: 6.526

2.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

3.  The economic costs of the health effects of smoking, 1984.

Authors:  D P Rice; T A Hodgson; P Sinsheimer; W Browner; A N Kopstein
Journal:  Milbank Q       Date:  1986       Impact factor: 4.911

4.  Alcohol-attributable mortality in France.

Authors:  Sylvie Guérin; Agnès Laplanche; Ariane Dunant; Catherine Hill
Journal:  Eur J Public Health       Date:  2013-03-04       Impact factor: 3.367

5.  [National study of screening practices for hepatitis C among hemodialysis patients. Hepatitis Group].

Authors:  N Ducret; S Mercier; C Colin; P Vergnon; C Laroche; F Bailly; A Caillette; M Labeeuw; C Trepo
Journal:  Nephrologie       Date:  1998

6.  Trends in tobacco-attributable mortality in France.

Authors:  Laureen Ribassin-Majed; Catherine Hill
Journal:  Eur J Public Health       Date:  2015-05-09       Impact factor: 3.367

  6 in total
  3 in total

1.  What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study.

Authors:  Jakob Manthey; Syed Ahmed Hassan; Sinclair Carr; Carolin Kilian; Sören Kuitunen-Paul; Jürgen Rehm
Journal:  Pharmacoeconomics       Date:  2021-05-10       Impact factor: 4.981

2.  Protocol for creating new warnings on cigarette packs and evaluating their efficacy in a randomised experimental setting.

Authors:  Christian Ben Lakhdar; Antoine Deplancke; Fabrice Le Lec; Sophie Massin; Anthony Piermatteo; Nicolas Vaillant
Journal:  BMJ Open       Date:  2020-06-28       Impact factor: 2.692

3.  Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER).

Authors:  Saskia Antwerpes; Marie Costa; Marion Coste; Morgane Bureau; Gwenaelle Maradan; Christophe Cutarella; Jacques Leloutre; Olivier Riccobono-Soulier; Sophie Hedoire; Elodie Frot; Fabienne Vernier; Stéphanie Vassas-Goyard; Tangui Barré; Danielle Casanova; Patrizia Carrieri
Journal:  Harm Reduct J       Date:  2022-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.